Evidence map›Paper›PMID 39011112›Full record

ArticleResearch square2024

Evaluating predictors of kinase activity of STK11 variants identified in primary human non-small cell lung cancers.

Yile Chen, Kyoungyeul Lee, Junwoo Woo, Dong-Wook Kim, Changwon Keum, Giulia Babbi, Rita Casadio, Pier Luigi Martelli, Castrense Savojardo, Matteo Manfredi and 13 more

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Yile ChenDepartment of Biomedical Informatics and Medical Education, University of Washington, Seattle, 98105, WA, USA.
Kyoungyeul Lee3billion, 3billion Biotechnology company, Seoul, South Korea.
Junwoo Woo3billion, 3billion Biotechnology company, Seoul, South Korea.
Dong-Wook Kim3billion, 3billion Biotechnology company, Seoul, South Korea.
Changwon Keum3billion, 3billion Biotechnology company, Seoul, South Korea.
Giulia BabbiDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, 40126, Italy.
Rita CasadioDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, 40126, Italy.
Pier Luigi MartelliDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, 40126, Italy.
Castrense SavojardoDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, 40126, Italy.
Matteo ManfrediDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, 40126, Italy.
Yang ShenDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, 77843, TX, USA.
Yuanfei SunDepartment of Electrical and Computer Engineering, Texas A&M University, College Station, 77843, TX, USA.
Panagiotis KatsonisMolecular and Human Genetics, Baylor College of Medicine, Houston, 77030, TX, USA.
Olivier LichtargeMolecular and Human Genetics, Baylor College of Medicine, Houston, 77030, TX, USA.
Vikas PejaverInstitute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA.
David J SewardDepartment of Pathology, University of Vermont, Burlington, 5445, VT, USA.
Akash KamandulaKhoury College of Computer Sciences, Northeastern University, Boston, 02115, MA, USA.
Constantina BakolitsaUniversity of California, Berkeley, Berkeley, 94720, CA, USA.
Steven E BrennerUniversity of California, Berkeley, Berkeley, 94720, CA, USA.
Predrag RadivojacKhoury College of Computer Sciences, Northeastern University, Boston, 02115, MA, USA.
Anne O'Donnell-LuriaDivision of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, 02115, MA, USA.
Sean D MooneyCenter for Information Technology, National Institutes of Health, Bethesda, 20892, MD, USA.
Shantanu JainKhoury College of Computer Sciences, Northeastern University, Boston, 02115, MA, USA.

Funding

Center for Critical Assessment of Genome InterpretationU24HG007346 · NHGRI · UNIVERSITY OF CALIFORNIA BERKELEY · PI BRENNER, STEVEN E, IOANNIDIS, NILAH MONNIER · 2020 to 2025
$3.8M
Supporting IGVF by modeling genetics, function, and phenotype with machine learningU01HG012022 · NHGRI · NORTHEASTERN UNIVERSITY · PI Predrag Radivojac · 2021 to 2026
$3.4M
Unraveling molecular and system-level mechanisms of human disease-associated protein mutationsR35GM124952 · NIGMS · TEXAS ENGINEERING EXPERIMENT STATION · PI Yang Shen · 2017 to 2026
$2.9M
NHGRI NIH HHS U01 HG012022NHGRI NIH HHS U24 HG007346NIGMS NIH HHS R35 GM124952
6 · The paper itself

Abstract

Critical evaluation of computational tools for predicting variant effects is important considering their increased use in disease diagnosis and driving molecular discoveries. In the sixth edition of the Critical Assessment of Genome Interpretation (CAGI) challenge, a dataset of 28 STK11 rare variants (27 missense, 1 single amino acid deletion), identified in primary non-small cell lung cancer biopsies, was experimentally assayed to characterize computational methods from four participating teams and five publicly available tools. Predictors demonstrated a high level of performance on key evaluation metrics, measuring correlation with the assay outputs and separating loss-of-function (LoF) variants from wildtype-like (WT-like) variants. The best participant model, 3Cnet, performed competitively with well-known tools. Unique to this challenge was that the functional data was generated with both biological and technical replicates, thus allowing the assessors to realistically establish maximum predictive performance based on experimental variability. Three out of the five publicly available tools and 3Cnet approached the performance of the assay replicates in separating LoF variants from WT-like variants. Surprisingly, REVEL, an often-used model, achieved a comparable correlation with the real-valued assay output as that seen for the experimental replicates. Performing variant interpretation by combining the new functional evidence with computational and population data evidence led to 16 new variants receiving a clinically actionable classification of likely pathogenic (LP) or likely benign (LB). Overall, the STK11 challenge highlights the utility of variant effect predictors in biomedical sciences and provides encouraging results for driving research in the field of computational genome interpretation.

Indexed as

CAGIcancerkinasemachine learningPeutz-Jeghers syndromeSTK11variant effect prediction

Identifiers

PMID39011112
PMCPMC11247923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.